Treatment of neuromyelitis optica: an evidence based review.
Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years Su-Hyun Kim, MD; Woojun Kim, MD, PhD; Xue Feng Li, MD, MSc; In-Ja Jung, RN; Ho Jin Kim, MD, PhD Arch Neurol. ?2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154 Objective? To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO).
Genetic analysis of aquaporin-4 in neuromyelitis optica. Matiello M , Schaefer-Klein JL , Hebrink DD , Kingsbury DJ , Atkinson EJ , Weinshenker BG ; On behalf of the NMO Genetics Collaborators
A population-based study of neuromyelitis optica in Caucasians N.
Objective: To determine anti-AQP4 antibody status in Thai patients with demyelinating diseases. Methods: Blood samples of patients visiting MS clinic at Siriraj Hospital, Thailand were collected and sent to Tohoku University for testing anti-AQP4 antibodies using AQP4-transfected cell-based assay. Diagnosis was as follows
SETTING: Neuromyelitis optica (NMO), or Devic’s disease, is a rare acute inflammatory disease characterised by demyelination affecting the spinal cord and optic nerves.
INTRODUCTION: Optic neuromyelitis or Devic’s syndrome is a very rare disease affecting the optic tracts and the spinal cord. Its association with evolving pulmonary tuberculosis has been reported in a handful of case reports.
Background: Association of the haplotype including DRB1*1501 with multiple sclerosis (MS) is well established. Recent studies have suggested lack of association of this haplotype with neuromyelitis optica (NMO) (Z?phir et al